|
Synonyms: CDP870 | Cimzia® | PHA 738144
certolizumab pegol is an approved drug (FDA (2008), EMA (2009))
Compound class:
Antibody
Comment: This therapeutic is a TNFα neutralising agent. Structurally it is a Fab' fragment of a TNFα-binding monoclonal antibody, which has polyethylene glycol (PEG) conjugated to a free cysteine residue in its hinge region (Cys227 of the heavy chain). Removing the Fc portion minimizes complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), two reactions known to cause unwanted side-effects in mAb therapies. PEGylation is used to increase the drug's half life, as Fab' fragments are normally rapidly degraded in vivo.
|
Classification ![]() |
|
| Compound class | Antibody |
| Approved drug? | Yes. US FDA (2008) | EU EMA (2009) |
| WHO Essential Medicine | WHO Essential Medicines List (EML) (24th List, 2025). Download PDF version. Click to view more information about the WHO Model Lists of Essential Medicines. |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 8448 | certolizumab pegol |
Synonyms ![]() |
| CDP870 | Cimzia® | PHA 738144 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 242 |
| Other databases | |
| GtoPdb PubChem SID | 178103380 |
| PubChem SID | 178103380 |
| Search PubMed clinical trials | certolizumab pegol |
| Search PubMed titles | certolizumab pegol |
| Search PubMed titles/abstracts | certolizumab pegol |
| Wikipedia | Certolizumab_pegol |